Guardant Health, Inc. (NASDAQ:GH – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $39.31.
GH has been the topic of several analyst reports. Craig Hallum increased their target price on shares of Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. TD Cowen increased their price objective on Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Citigroup boosted their target price on Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. The Goldman Sachs Group increased their price target on Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Finally, Stephens restated an “overweight” rating and issued a $44.00 price objective on shares of Guardant Health in a research note on Friday, May 24th.
Check Out Our Latest Stock Analysis on GH
Hedge Funds Weigh In On Guardant Health
Guardant Health Price Performance
NASDAQ GH opened at $26.79 on Friday. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.40 and a quick ratio of 6.07. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of -6.83 and a beta of 1.11. The company has a 50 day simple moving average of $29.23 and a 200-day simple moving average of $24.75. Guardant Health has a 52-week low of $15.81 and a 52-week high of $37.04.
Guardant Health (NASDAQ:GH – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The company had revenue of $177.24 million during the quarter, compared to analyst estimates of $162.59 million. Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The company’s revenue was up 29.2% compared to the same quarter last year. During the same period last year, the company posted ($0.67) earnings per share. Equities research analysts predict that Guardant Health will post -3.3 earnings per share for the current fiscal year.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading
- Five stocks we like better than Guardant Health
- What does consumer price index measure?
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- What is a SEC Filing?
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What is a buyback in stocks? A comprehensive guide for investors
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.